Sun Pharmaceutical Industries Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook

Sun Pharmaceutical Industries share price prediction 2027 comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 1,761.00 on NSE as of 9 October 2026, 14.0% below its 52-week high of Rs 2,046.90, after the company reported net profit of Rs 11,564.52 crore for FY26.

This Sun Pharmaceutical Industries stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.

Click Here – Get Free Investment Predictions

Sun Pharmaceutical Industries Share Price Today and Key Data

The Sun Pharmaceutical Industries share price today is Rs 1,761.00 on NSE, up 0.07% on the day. The market capitalisation stands at Rs 4,20,483 crore. Over the past year the price has risen 6.2% from Rs 1,658.50. Every Sun Pharmaceutical Industries stock forecast figure below starts from this price.

Metric	Value
Company	Sun Pharmaceutical Industries (SUNPHARMA)
Current Price	Rs 1,761.00
52-Week High	Rs 2,046.90 (31 July 2026)
52-Week Low	Rs 1,583.70 (29 January 2026)
Market Cap	Rs 4,20,483 crore
PE Ratio	34.70
Industry PE	37.59
PB Ratio	5.03
EPS (TTM)	Rs 50.50
Return on Equity	13.74%
Debt to Equity	0.06
Dividend Yield	0.91%
Book Value per Share	Rs 348.31

What Is the Sun Pharmaceutical Industries Share Price Prediction for 2027?

The Sun Pharmaceutical Industries share price prediction for 2027 is a conservative case of Rs 1,846, a base case of Rs 2,113 and a bull case of Rs 2,385. Against Rs 1,761.00, these imply 4.8% upside, 20.0% upside and 35.4% upside. They are model scenarios built from reported EPS growth, not broker targets.

Scenario	EPS Growth Basis	EPS Estimate	PE Multiple	Implied Value	Upside vs Current Price
Conservative Case	Lower of FY26 growth (4.8%) and 4-year CAGR (36.9%)	Rs 52.94 (+4.8%)	Unchanged from today (price to EPS ratio kept constant)	Rs 1,846	+4.8%
Base Case	Average of the two (capped at 20%)	Rs 60.60 (+20.0%)	Unchanged from today (price to EPS ratio kept constant)	Rs 2,113	+20.0%
Bull Case	Higher of the two (capped at 25%)	Rs 63.12 (+25.0%)	Re-rated 8.3% toward industry PE of 37.59 (still at or below it)	Rs 2,385	+35.4%

Each target takes today's price of Rs 1,761.00 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 4-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. The bull case also re-rates the PE multiple toward the industry level, because the stock trades below it. Together they form the Sun Pharmaceutical Industries target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.

Sun Pharmaceutical Industries Share Price Forecast: What Has to Go Right by 2027

Each Sun Pharmaceutical Industries target price below depends on a specific EPS outcome, and the text states that outcome next to the number.

Conservative Case for the Sun Pharmaceutical Industries Share Price Target: Rs 1,846

Reaching Rs 1,846 needs EPS to rise 4.8% to Rs 52.94 while the stock keeps its current PE multiple. That matches the FY26 EPS growth of 4.8%.

Base Case for the Sun Pharmaceutical Industries Share Price Target: Rs 2,113

Reaching Rs 2,113 needs EPS to rise 20.0% to Rs 60.60, the average of the FY26 growth rate and the 4-year CAGR. Net profit growth of 26.4% in Q1 FY27 is at or above that pace, which supports the target.

Bull Case for the Sun Pharmaceutical Industries Share Price Target: Rs 2,385

Reaching Rs 2,385 needs EPS to rise 25.0% to Rs 63.12 and the PE multiple to re-rate 8.3% toward the industry PE. That is above the 52-week high of Rs 2,046.90, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 1,825.54 (200-day EMA) would be the first technical confirmation.

Sun Pharmaceutical Industries Financial Performance: Revenue, Profit and Margins

Sun Pharmaceutical Industries earned net profit of Rs 11,564.52 crore on revenue of Rs 61,673.94 crore in FY26, with profit up 5.3% and revenue up 12.7% compared with FY25. Diluted EPS was Rs 47.80 against Rs 45.60 a year earlier, and that earnings base anchors the Sun Pharmaceutical Industries share price forecast.

Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Operating Margin	Net Margin
FY22	39,729.96	3,405.82	13.60	29.19%	8.57%
FY23	44,520.20	8,560.84	35.30	27.59%	19.23%
FY24	49,887.17	9,648.44	39.90	28.63%	19.34%
FY25	54,729.01	10,980.10	45.60	31.49%	20.06%
FY26	61,673.94	11,564.52	47.80	31.47%	18.75%

In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 16,023.50 crore against Rs 14,315.86 crore a year earlier (+11.9%), and the bottom line was a net profit of Rs 2,910.80 crore against a net profit of Rs 2,302.62 crore (+26.4%). Operating margin was 32.52% versus 28.64% in the year-ago quarter. Cash flow from operations was Rs 12,419.18 crore in FY26 against Rs 14,072.09 crore in FY25. Together these figures set the earnings base for the Sun Pharmaceutical Industries share price prediction.

Check the Univest Screener for live Sun Pharmaceutical Industries fundamentals

Is Sun Pharmaceutical Industries Overvalued or Undervalued Right Now?

Sun Pharmaceutical Industries trades at a PE of 34.70 against an industry PE of 37.59, which places the stock at a 7.7% discount to the industry average. The price-to-book ratio is 5.03 on a book value of Rs 348.31 per share. Return on equity of 13.74% means the company earns Rs 13.74 of profit for every Rs 100 of shareholder equity.

Debt to equity is 0.06, so borrowings equal about 6% of shareholder equity. The company declared a dividend of Rs 16.00 per share for FY26, a yield of 0.91% at the current price. This valuation context frames the Sun Pharmaceutical Industries stock price prediction for 2027 without relying on any outside forecast.

Sun Pharmaceutical Industries Stock Analysis: Technical Outlook

Sun Pharmaceutical Industries stock trades below its 50-day SMA of Rs 1,887.31 and below its 200-day EMA of Rs 1,825.54, and the combined daily indicators read bearish. The 52-week high of Rs 2,046.90 was set on 31 July 2026, while the 52-week low of Rs 1,583.70 came on 29 January 2026.

Indicator	Reading	Signal
RSI (14)	36.79	Weak momentum
MACD (12,26,9)	-32.36 vs signal -25.60	Bearish
ADX (14)	42.57	Established trend
Supertrend (10,3)	Price below Rs 1,860.44	Bearish
50-day SMA	Rs 1,887.31	Price below
200-day EMA	Rs 1,825.54	Price below

The nearest support level sits at Rs 1,583.70 (52-week low). The nearest resistance level sits at Rs 1,825.54 (200-day EMA) and Rs 1,860.44 (Supertrend). A sustained move above the nearest resistance would support the Sun Pharmaceutical Industries share price prediction 2027 base case, and this Sun Pharmaceutical Industries stock analysis uses daily candles only. Chart signals add context to the Sun Pharmaceutical Industries share price target without changing the earnings maths.

Sun Pharmaceutical Industries Shareholding Pattern

Promoters hold 54.48% of Sun Pharmaceutical Industries as of Jun 2026, unchanged across the last 5 quarters. FII holding is 14.53% (down from 17.26% in Jun 2025) and DII holding is 22.18% (up from 19.50% in Jun 2025), which puts combined institutional holding at 36.71%. Public shareholders own 8.81%. Shareholding data is one input for any Sun Pharmaceutical Industries stock forecast.

Key Risks to the Sun Pharmaceutical Industries Share Price Target for 2027

Earnings and Margin Risk

Operating margin has ranged from 27.59% to 31.49% between FY22 and FY26, so a slip toward the lower end would trim the EPS estimate behind the Sun Pharmaceutical Industries stock forecast. Revenue was up 12.7% in FY26, and slower revenue growth would weigh on the profit path.

Size and Liquidity Risk

Market capitalisation stands at Rs 4,20,483 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any Sun Pharmaceutical Industries stock price target.

Balance Sheet Risk

Debt to equity of 0.06 means borrowings stand at about 6% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the Sun Pharmaceutical Industries share price forecast.

Technical Risk

The daily indicators read bearish, so the targets above may need a technical turn before the price follows earnings. A daily close below Rs 1,583.70 (52-week low) would weaken the setup further.

Conclusion

This Sun Pharmaceutical Industries stock analysis puts the share price target range for 2027 at Rs 1,846 to Rs 2,385, with a base case of Rs 2,113 against Rs 1,761.00 today. The inputs are a PE of 34.70 that sits at a 7.7% discount to the industry average, EPS growth of 4.8% in FY26 and a daily technical setup that reads bearish. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.

Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries live price and get daily stock recommendations.

Frequently Asked Questions on Sun Pharmaceutical Industries Share Price Prediction 2027

What is the Sun Pharmaceutical Industries share price target for 2027?

Ans. The Sun Pharmaceutical Industries share price forecast for 2027 has a conservative case of Rs 1,846, a base case of Rs 2,113 and a bull case of Rs 2,385. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.

What is the Sun Pharmaceutical Industries share price today?

Ans. Sun Pharmaceutical Industries trades at Rs 1,761.00 on NSE as of 9 October 2026, up 0.07% on the day. The 52-week range is Rs 1,583.70 to Rs 2,046.90.

Is Sun Pharmaceutical Industries a good stock to buy for 2027?

Ans. The data points in different directions: the PE of 34.70 is at a 7.7% discount to the industry average, EPS grew 4.8% in FY26 and the daily technical setup reads bearish. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.

Can Sun Pharmaceutical Industries stock reach Rs 2,385 in 2027?

Ans. Reaching Rs 2,385 needs EPS to rise 25.0% from Rs 50.50 and the PE multiple to re-rate toward the industry PE of 37.59, plus a daily close above Rs 1,825.54 (200-day EMA). This is a scenario, not a guarantee.

What are the support and resistance levels for Sun Pharmaceutical Industries?

Ans. The nearest support levels are Rs 1,583.70 (52-week low), and the nearest resistance levels are Rs 1,825.54 (200-day EMA) and Rs 1,860.44 (Supertrend).

What are the main risks for Sun Pharmaceutical Industries stock in 2027?

Ans. The main risks to the Sun Pharmaceutical Industries share price forecast are a fall in operating margin from the 27.59% to 31.49% range seen since FY22, slower revenue growth after FY26 revenue was up 12.7%, and thin trading volumes. Debt to equity of 0.06 adds balance sheet sensitivity.

How is the Sun Pharmaceutical Industries target price for 2027 calculated?

Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 4.8% growth, the base case 20.0% and the bull case 25.0%, all drawn from the company's reported FY26 and 4-year EPS growth.